Annual CFO
-$6.38 M
+$3.44 M+35.02%
December 31, 2023
Summary
- As of February 25, 2025, AQST annual cash flow from operations is -$6.38 million, with the most recent change of +$3.44 million (+35.02%) on December 31, 2023.
- During the last 3 years, AQST annual CFO has risen by +$39.08 million (+85.97%).
- AQST annual CFO is now -209.55% below its all-time high of $5.82 million, reached on December 31, 2017.
Performance
AQST Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$11.88 M
-$4.87 M-69.57%
September 30, 2024
Summary
- As of February 25, 2025, AQST quarterly cash flow from operations is -$11.88 million, with the most recent change of -$4.87 million (-69.57%) on September 30, 2024.
- Over the past year, AQST quarterly CFO has dropped by -$9.53 million (-406.18%).
- AQST quarterly CFO is now -176.02% below its all-time high of $15.63 million, reached on September 30, 2017.
Performance
AQST Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$34.21 M
-$9.53 M-38.63%
September 30, 2024
Summary
- As of February 25, 2025, AQST TTM cash flow from operations is -$34.21 million, with the most recent change of -$9.53 million (-38.63%) on September 30, 2024.
- Over the past year, AQST TTM CFO has dropped by -$41.19 million (-590.28%).
- AQST TTM CFO is now -353.82% below its all-time high of $13.48 million, reached on March 31, 2023.
Performance
AQST TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
AQST Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +35.0% | -406.2% | -590.3% |
| 3 y3 years | +86.0% | -406.2% | -590.3% |
| 5 y5 years | +50.9% | -406.2% | -590.3% |
AQST Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +80.7% | -234.8% | +18.0% | -353.8% | +10.4% |
| 5 y | 5-year | at high | +89.4% | -234.8% | +18.0% | -353.8% | +43.2% |
| alltime | all time | -209.6% | +89.4% | -176.0% | +32.8% | -353.8% | +43.2% |
Aquestive Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$11.88 M(+69.6%) | -$34.21 M(+38.6%) |
| Jun 2024 | - | -$7.01 M(-32.5%) | -$24.68 M(-3.5%) |
| Mar 2024 | - | -$10.38 M(+110.1%) | -$25.58 M(+300.9%) |
| Dec 2023 | -$6.38 M(-35.0%) | -$4.94 M(+110.6%) | -$6.38 M(-191.4%) |
| Sep 2023 | - | -$2.35 M(-70.3%) | $6.98 M(-42.5%) |
| Jun 2023 | - | -$7.91 M(-189.7%) | $12.13 M(-10.0%) |
| Mar 2023 | - | $8.82 M(+4.8%) | $13.48 M(-237.3%) |
| Dec 2022 | -$9.82 M(-70.2%) | $8.42 M(+199.6%) | -$9.82 M(-62.7%) |
| Sep 2022 | - | $2.81 M(-142.8%) | -$26.30 M(-31.1%) |
| Jun 2022 | - | -$6.56 M(-54.7%) | -$38.17 M(+14.4%) |
| Mar 2022 | - | -$14.48 M(+79.7%) | -$33.36 M(+1.2%) |
| Dec 2021 | -$32.98 M(-27.5%) | -$8.06 M(-11.1%) | -$32.98 M(-14.2%) |
| Sep 2021 | - | -$9.06 M(+416.2%) | -$38.43 M(+2.0%) |
| Jun 2021 | - | -$1.76 M(-87.5%) | -$37.68 M(-17.9%) |
| Mar 2021 | - | -$14.10 M(+4.3%) | -$45.92 M(+1.0%) |
| Dec 2020 | -$45.46 M | -$13.51 M(+62.5%) | -$45.46 M(+6.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$8.31 M(-16.8%) | -$42.52 M(-13.2%) |
| Jun 2020 | - | -$10.00 M(-26.7%) | -$49.00 M(-12.8%) |
| Mar 2020 | - | -$13.64 M(+29.0%) | -$56.17 M(-6.7%) |
| Dec 2019 | -$60.21 M(+363.5%) | -$10.57 M(-28.5%) | -$60.21 M(+14.8%) |
| Sep 2019 | - | -$14.79 M(-13.8%) | -$52.45 M(+6.7%) |
| Jun 2019 | - | -$17.17 M(-2.9%) | -$49.13 M(+56.2%) |
| Mar 2019 | - | -$17.68 M(+528.7%) | -$31.46 M(+142.1%) |
| Dec 2018 | -$12.99 M(-323.1%) | -$2.81 M(-75.5%) | -$12.99 M(-26.1%) |
| Sep 2018 | - | -$11.47 M(-2345.6%) | -$17.59 M(-284.9%) |
| Jun 2018 | - | $511.00 K(-34.9%) | $9.51 M(+252.2%) |
| Mar 2018 | - | $785.00 K(-110.6%) | $2.70 M(-53.6%) |
| Dec 2017 | $5.82 M(-171.2%) | -$7.41 M(-147.4%) | $5.82 M(-56.0%) |
| Sep 2017 | - | $15.63 M(-348.0%) | $13.23 M(-652.8%) |
| Jun 2017 | - | -$6.30 M(-261.3%) | -$2.39 M(-161.3%) |
| Mar 2017 | - | $3.91 M | $3.91 M |
| Dec 2016 | -$8.18 M | - | - |
FAQ
- What is Aquestive Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Aquestive Therapeutics?
- What is Aquestive Therapeutics annual CFO year-on-year change?
- What is Aquestive Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Aquestive Therapeutics?
- What is Aquestive Therapeutics quarterly CFO year-on-year change?
- What is Aquestive Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Aquestive Therapeutics?
- What is Aquestive Therapeutics TTM CFO year-on-year change?
What is Aquestive Therapeutics annual cash flow from operations?
The current annual CFO of AQST is -$6.38 M
What is the all time high annual CFO for Aquestive Therapeutics?
Aquestive Therapeutics all-time high annual cash flow from operations is $5.82 M
What is Aquestive Therapeutics annual CFO year-on-year change?
Over the past year, AQST annual cash flow from operations has changed by +$3.44 M (+35.02%)
What is Aquestive Therapeutics quarterly cash flow from operations?
The current quarterly CFO of AQST is -$11.88 M
What is the all time high quarterly CFO for Aquestive Therapeutics?
Aquestive Therapeutics all-time high quarterly cash flow from operations is $15.63 M
What is Aquestive Therapeutics quarterly CFO year-on-year change?
Over the past year, AQST quarterly cash flow from operations has changed by -$9.53 M (-406.18%)
What is Aquestive Therapeutics TTM cash flow from operations?
The current TTM CFO of AQST is -$34.21 M
What is the all time high TTM CFO for Aquestive Therapeutics?
Aquestive Therapeutics all-time high TTM cash flow from operations is $13.48 M
What is Aquestive Therapeutics TTM CFO year-on-year change?
Over the past year, AQST TTM cash flow from operations has changed by -$41.19 M (-590.28%)